These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36611247)

  • 1. Systemic Activation of the Kynurenine Pathway in Graves Disease With and Without Ophthalmopathy.
    Ueland HO; Ulvik A; Løvås K; Wolff ASB; Breivik LE; Stokland AM; Rødahl E; Nilsen RM; Husebye E; Ueland GÅ
    J Clin Endocrinol Metab; 2023 May; 108(6):1290-1297. PubMed ID: 36611247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
    Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Looking Beyond Th17 Cells: A Role for Th17.1 Cells in Thyroid-associated Ophthalmopathy?
    Jiang M; Fu Y; Wang P; Yan Y; Zhao J; Wang Y; Yan S
    Endocrinology; 2023 Jan; 164(3):. PubMed ID: 36624983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokines in thyroid autoimmunity.
    Ferrari SM; Paparo SR; Ragusa F; Elia G; Mazzi V; Patrizio A; Ghionzoli M; Varricchi G; Centanni M; Ulisse S; Antonelli A; Fallahi P
    Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101773. PubMed ID: 36907786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel inflammatory biomarkers in thyroid eye disease.
    Ueland HO; Ueland GÅ; Løvås K; Breivk LE; Thrane AS; Meling Stokland AE; Rødahl E; Husebye ES
    Eur J Endocrinol; 2022 Aug; 187(2):293-300. PubMed ID: 35675127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapies for Thyroid Autoimmune Diseases.
    Fallahi P; Ferrari SM; Elia G; Nasini F; Colaci M; Giuggioli D; Vita R; Benvenga S; Ferri C; Antonelli A
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):853-61. PubMed ID: 26900630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biomarkers of Graves' ophthalmopathy.
    Longo CM; Higgins PJ
    Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
    Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
    PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
    He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
    Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
    Heisel CJ; Riddering AL; Andrews CA; Kahana A
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipids in thyroid eye disease.
    Gulbins A; Görtz GE; Gulbins E; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1170884. PubMed ID: 37082124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.
    Craps J; Joris V; Baldeschi L; Daumerie C; Camboni A; Buemi A; Lengelé B; Behets C; Boschi A; Mourad M; Many MC; Dessy C
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease.
    Zhang Y; Fu Y; Yang Y; Ke J; Zhao D
    J Int Med Res; 2022 Jul; 50(7):3000605221112031. PubMed ID: 35903860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
    Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
    Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR6 within T-helper (Th) and T-cytotoxic (Tc) type 1 lymphocytes in Graves' disease (GD).
    Aust G; Kamprad M; Lamesch P; Schmücking E
    Eur J Endocrinol; 2005 Apr; 152(4):635-43. PubMed ID: 15817921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells.
    Sun Z; Zhong W; Lu X; Shi B; Zhu Y; Chen L; Zhang G; Zhang X
    J Clin Immunol; 2008 Sep; 28(5):464-72. PubMed ID: 18704663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.